Tigecycline: A critical safety review

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 335-342

  Kaewpoowat, Quanhathai ^a   Ostrosky Zeichner, Luis ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adverse reactions; Drugs interactions; Safety evaluation; Tigecycline

Indexed keywords

CONTRACEPTIVE AGENT; CYCLOSPORIN; DIGOXIN; TIGECYCLINE; WARFARIN; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; BRAIN PSEUDOTUMOR; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PHOTOSENSITIVITY; REVIEW; SEPSIS; SIDE EFFECT; SKIN INFECTION; STEVENS JOHNSON SYNDROME; TOOTH DISCOLORATION; TREATMENT INDICATION; VOMITING; ANALOGS AND DERIVATIVES; DRUG INTERACTION;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; HUMANS; MINOCYCLINE;

EID: 84921416194     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.997206     Document Type: Review

References (52)

1. Carlet J, Jarlier V, Harbarth S, et al. Ready for a world without antibiotics? The pensières antibiotic resistance call to action. Antimicrob Resist Infect Control 2012;1(1):11
2. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004;24(1):58-68
3. Tigecycline (Marketed as Tygacil) Information. Postmarket drug safety information for patients and providers. FDA/center for drug evaluation and research. 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm224383.htm [Last accessed 10 March 2014]
4. Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics used to Treat Similar Infections. FDA drug safety and availability. FDA/center for drug evaluation and research. 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm [Last accessed 10 March 2014]
5. FDA Warns of Increased Risk of Death With IV Antibacterial Tygacil (Tigecycline) and Approves new Boxed Warning. FDA drug safety communication. FDA/center for drug evaluation and research. 2013. Available from: http://www.fda.gov/drugs/drugsafety/ucm369580.htm [Last accessed 10 March 2014]
6. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-6
7. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9
8. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005;17(Suppl 1):12-22
9. Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol 2011;51:93-101
10. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44
11. Rubino CM, Bhavnani SM, Forrest A, et al. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob Agents Chemother 2012;56:130-6
12. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against chlamydia pneumoniae and chlamydia trachomatis. Int J Antimicrob Agents 2000;16:61-3
13. Sader HS, Farrell DJ, Flamm RK, et al. Tigecycline activity when tested against bacterial strains from united states medical centers: variation in potency and spectrum since approval for clinical use (2006-2012). Antimicrob Agents Chemother 2014;doi: 10.1128/AAC.02684-13
14. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
15. Babinchak T, Ellis-Grosse E, Dartois N, et al. Tigecycline 301 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67
16. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 Phase III studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-38
17. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51
18. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006;38:1081-4
19. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50
20. Polidori M, Nuccorini A, Tascini C, et al. Vancomycin-resistant enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother Florence Italy 2011;23:240-1
21. Cocchi S, Bisi L, Codeluppi M, et al. Brucellosis in a patient with end-stage liver disease undergoing liver transplantation: successful treatment with tigecycline. Liver Transpl 2010;16:1215-16
22. Russo G, Lichtner M, Carnevalini M, et al. Primary retroperitoneal abscesses due to rhodococcus equi in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline. Int J Infect Dis 2010;14:e533-5
23. Debast SB, Bauer MP, Kuijper EJ, et al. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for clostridium difficile infection. Clin Microbiol Infect 2014;20:1-26
24. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009;88:211-20
25. Petersen PJ, Labthavikul P, Jones CH, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57:573-6
26. Vouillamoz J, Moreillon P, Giddey M, et al. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 2008;61:371-4
27. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34:8.e1-9
28. Zimmerman JJ, Raible DG, Harper DM, et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy 2008;28:895-905
29. Zimmerman JJ, Harper DM, Matschke K, et al. Absence of an interaction between tigecycline and digoxin in healthy men. Pharmacotherapy 2007;27:835-44
30. Stumpf AN, Schmidt C, Hiddemann W, et al. High serum concentrations of cyclosporin related to administration of tigecycline. Eur J Clin Pharmacol 2009;65:101-3
31. Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant staphylococcus aureus infections during lactation: safety in breastfeeding infants. Pharmacotherapy 2009;29:1103-9
32. Guirao X, García MS, Bassetti M, et al. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five european observational studies. J Antimicrob Chemother 2013;68:ii37-44
33. Kadoyama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data mining of the public version of the US FDA adverse event reporting system. Biol Pharm Bull 2012;35:967-70
34. McGovern PC, Wible M, Korth-Bradley JM, et al. Pancreatitis in tigecycline Phase III and IV clinical studies. J Antimicrob Chemother 2014;69:773-8
35. Bonilla MF, Avery RK, Rehm SJ, et al. Extreme alkaline phosphatase elevation associated with tigecycline. J Antimicrob Chemother 2011;66:952-3
36. Korth-Bradley JM, McGovern PC, Salageanu J, et al. Tigecycline does not prolong corrected QT intervals in healthy subjects. Antimicrob Agents Chemother 2013;57:1895-901
37. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34:496-507
38. Maximova N, Zanon D, Verzegnassi F, et al. Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients. J Pediatr Hematol Oncol 2013;35:e33-7
39. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62(Suppl 1):i17-28
40. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-72
41. Tastina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44
42. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71
43. Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709
44. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012;54:1672-4
45. McGovern PC, Wible M, El-Tahtawy A, et al. All-cause mortality imbalance in the tigecycline Phase III and IV clinical trials. Int J Antimicrob Agents 2013;41:463-7
46. Gardiner D, Dukart G, Cooper A, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 Phase III clinical trials. Clin Infect Dis 2010;50:229-38
47. Martín-Gandul C, García-Cabrera E, Castillo-Ojeda E, et al. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. J Antimicrob Chemother 2012;67:1048-9
48. Falagas ME, Vardakas KZ, Tsiveriotis KP, et al. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014;44(1):1-7
49. Eckmann C, Heizmann WR, Leitner E, et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 2011;57:275-84
50. Powers JH. Editorial commentary: asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials. Clin Infect Dis 2012;54:1710-13
51. Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009;34:101-2
52. Verde PE, Curcio D. Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis. Clin Infect Dis 2012;55:471-2